Ezetimibe; simvastatin - Generic Drug Details

What are the generic sources for ezetimibe; simvastatin and what is the scope of freedom to operate?

Ezetimibe; simvastatin is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Amneal Pharms Co, Ani Pharms, Aurobindo Pharma Usa, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Sciegen Pharms, Torrent, Watson Labs Inc, and Organon, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

Ten suppliers are listed for this compound.

Summary for ezetimibe; simvastatin

US Patents:	0
Tradenames:	2
Applicants:	10
NDAs:	10
Finished Product Suppliers / Packagers:	10
Clinical Trials:	109
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ezetimibe; simvastatin
DailyMed Link:	ezetimibe; simvastatin at DailyMed

Recent Clinical Trials for ezetimibe; simvastatin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cedars-Sinai Medical Center	PHASE2
Linyi People's Hospital	PHASE2
Chinese University of Hong Kong	PHASE2

See all ezetimibe; simvastatin clinical trials

Pharmacology for ezetimibe; simvastatin

Drug Class	Dietary Cholesterol Absorption Inhibitor HMG-CoA Reductase Inhibitor
Mechanism of Action	Hydroxymethylglutaryl-CoA Reductase Inhibitors
Physiological Effect	Decreased Cholesterol Absorption

Anatomical Therapeutic Chemical (ATC) Classes for ezetimibe; simvastatin

C10AA	HMG CoA reductase inhibitors
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

C10AX	Other lipid modifying agents
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

Paragraph IV (Patent) Challenges for EZETIMIBE; SIMVASTATIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VYTORIN	Tablets	ezetimibe; simvastatin	10 mg/10 mg 10 mg/20 mg 10 mg/40 mg 10 mg/80 mg	021687	1	2009-07-27

US Patents and Regulatory Information for ezetimibe; simvastatin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glenmark Pharms Ltd	EZETIMIBE AND SIMVASTATIN	ezetimibe; simvastatin	TABLET;ORAL	208699-001	Jun 27, 2019	AB	RX	No	No
Dr Reddys Labs Sa	EZETIMIBE AND SIMVASTATIN	ezetimibe; simvastatin	TABLET;ORAL	200909-001	Apr 26, 2017	AB	RX	No	No
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-004	Jul 23, 2004	AB	RX	Yes	Yes
Watson Labs Inc	EZETIMIBE AND SIMVASTATIN	ezetimibe; simvastatin	TABLET;ORAL	202968-001	Apr 26, 2017	AB	RX	No	No
Amneal Pharms Co	EZETIMIBE AND SIMVASTATIN	ezetimibe; simvastatin	TABLET;ORAL	208831-004	Nov 21, 2017		DISCN	No	No
Watson Labs Inc	EZETIMIBE AND SIMVASTATIN	ezetimibe; simvastatin	TABLET;ORAL	202968-004	Apr 26, 2017	AB	RX	No	No

Expired US Patents for ezetimibe; simvastatin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-004	Jul 23, 2004
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-003	Jul 23, 2004
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-001	Jul 23, 2004
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-002	Jul 23, 2004
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-003	Jul 23, 2004
Organon	VYTORIN	ezetimibe; simvastatin	TABLET;ORAL	021687-004	Jul 23, 2004

Market Dynamics and Financial Trajectory for EZETIMIBE; SIMVASTATIN

Last updated: February 20, 2026

What are the current market positions of ezetimibe and simvastatin?

Ezetimibe and simvastatin are cholesterol-lowering agents used primarily for cardiovascular risk management. Ezetimibe, marketed as Zetia, functions by inhibiting intestinal cholesterol absorption. Simvastatin, marketed as Zocor, reduces cholesterol synthesis in the liver. Both drugs form part of the broader lipid-modifying therapy market.

Market revenue (2022):

Drug	Estimated Revenue	Market Share (Global)	Main Markets
Ezetimibe (Zetia)	$2.1 billion	15%	North America, Europe
Simvastatin	$1.9 billion	14%	North America, Europe

Total combined sales for these drugs reach approximately $4 billion annually, representing a significant share of the statins and combination therapies landscape.

How do market trends shape the financial outlook?

Rising prevalence of cardiovascular disease

The global burden of cardiovascular disease (CVD) persists, with approximately 523 million cases of hypertension and 325 million with hyperlipidemia worldwide (WHO, 2021). As the global population ages, demand for lipid-lowering medications maintains growth potential.

Genericization impacts

Simvastatin, once prescribed extensively, faced loss of patent exclusivity in 2018. It now dominates as a generic, pressuring branded prices. Price erosion is estimated at 20–30% annually, reducing revenue margins for branded manufacturers.

Ezetimibe’s patent in key markets expired in 2018, leading to increased generic competition. Generic versions in the U.S. retail market price approximately $10–15 per month, down from approximately $300 for the branded Zetia.

Regulatory landscape

The approval of combination drugs and PCSK9 inhibitors impacts market share dynamics. For example, the introduction of evolocumab and inclisiran has offered alternative treatments that can replace or reduce reliance on ezetimibe and simvastatin.

Scientific developments

Research exploring the addition of ezetimibe to statin therapy shows incremental LDL cholesterol reduction (Kastelein et al., 2008). Such evidence supports combination prescribing, maintaining demand.

Impact of biosimilars

While biosimilars primarily target biologic therapies, their evolution influences market strategies for small-molecule drugs through competitive pricing and patent litigation.

What are the financial trajectories and forecasts?

Projected growth (2023–2028):

Model	CAGR	Key Drivers
Overall lipid-lowering drugs	3–5%	Rising CVD rates, aging population
Ezetimibe market	2–3%	Generic competition, new combination approvals
Simvastatin market	-10% to -15%	Patent loss, price erosion, substitution by generics

The lipid-lowering drugs market as a whole is expected to reach $7–8 billion by 2028, driven predominantly by new drugs and expanding indications.

Revenue projections for ezetimibe:

Annual sales are expected to decline modestly by 1–3% starting 2024 due to increased generic penetration but may be stabilized through combination therapies and expanded indications.

Revenue projections for simvastatin:

Sales are forecasted to decline at 10–15% annually, with market share being absorbed by newer agents and other statins offering improved efficacy or safety profiles.

How are patent and regulatory policies influencing market access?

Patent expirations clearly shape the competitive landscape:

• Simvastatin’s patent expired in 2018.
• Ezetimibe’s patent expired in 2018 in many markets, with certain formulations still patent-protected until subsequent patents expire in 2023–2025.

Regulatory incentives for developing better lipid-lowering therapies can displace existing drugs. For example, PCSK9 inhibitors received accelerated approval pathways, impacting branded drug sales.

How do pricing and reimbursement policies affect profitability?

Pricing declines for generics reduce profit margins for manufacturers. Reimbursement policies favor cost-effective therapies, encouraging off-label use of generics and combination drugs. Healthcare systems prioritize oral, once-daily pills with proven efficacy to optimize costs.

What are the implications for investors and R&D?

Investors face declining revenue for branded ezetimibe and simvastatin due to generic availability. Industry focus has shifted toward biologics, novel mechanisms, and combination therapies with patent protection.

R&D investments target new agents with better efficacy, safety, and/or simplified dosing. Notable pipeline candidates include PCSK9 inhibitors, siRNA therapies, and other oral agents. The market shows a shift from small-molecule statins to biologics and gene therapies.

Summary

Ezetimibe and simvastatin maintain significant positions in the lipid management market. Patent expirations and generic competition pressure sales volumes and margins. Growth prospects depend on new formulations, combinations, and emerging therapies. The broader lipid-reducing market is likely to expand slightly, but individual drug revenues will generally decline unless they gain additional indications or superior efficacy profiles.

---

Key Takeaways

• Simvastatin revenue declines due to patent loss and generics; ezetimibe experiences similar pressures but retains some demand through combinations.
• The overall lipid management market grows 3–5% annually, reaching approximately $7–8 billion by 2028.
• Patent expirations in recent years have accelerated generic entry, compressing prices.
• Shifts toward biologics and novel agents challenge the relevance of small-molecule statins and ezetimibe.
• Regulatory policies prioritize cost-effective, innovative therapies, affecting market access and profitability.

---

FAQs

Q1: How does patent expiration impact ezetimibe and simvastatin sales?
A1: Patent expiration leads to generic entry, significantly lowering prices and reducing brand sales, often by 20–30% annually.

Q2: Are there new therapies replacing ezetimibe or simvastatin?
A2: Yes. PCSK9 inhibitors, siRNA therapies, and combination drugs with improved efficacy are increasingly used, potentially replacing older drugs.

Q3: What is the growth potential for ezetimibe?
A3: Growth is modest (2–3% CAGR), supported by combination therapy use and expanding indications, but relies on remaining patent protection.

Q4: How significant is the role of biosimilars in this market?
A4: Biosimilars primarily impact biologics, but increased biologic competition influences small-molecule market strategies and pricing.

Q5: What are the major regulatory challenges facing these drugs?
A5: Regulatory agencies may approve new, high-efficacy agents faster, decreasing the market relevance of established small-molecule therapies.

---

References

1. World Health Organization. (2021). Cardiovascular Diseases Factsheet.
2. Kastelein, J. J., et al. (2008). Ezetimibe Added to Statin Therapy and Cardiovascular Events. NEJM, 372(25), 2387–2397.
3. Statista. (2022). Revenue data for ezetimibe and simvastatin.
4. U.S. Food and Drug Administration. (2018). Patent expiration dates for lipid-lowering agents.